Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1696 to 1710 of 2008 results for nice guidelines

  1. Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  2. Cystic fibrosis: long-term azithromycin (ESUOM37)

    This evidence summary has been updated and replaced by NICE guideline NG78.

    Withdrawn advice

  3. Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine (ESUOM40)

    This evidence summary has been updated and replaced by NICE guideline NG97.

    Withdrawn advice

  4. Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Withdrawn advice

  5. Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)

    This evidence summary has been updated and replaced by NICE guideline NG131.

    Withdrawn advice

  6. Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8)

    This evidence summary has been updated and replaced by NICE guideline NG87.

    Withdrawn advice

  7. Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events (TA90)

    This guideline has been updated and replaced by NICE technology appraisal 210.

    Withdrawn guidance

  8. Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Withdrawn advice

  9. Rapid tranquillisation in mental health settings: promethazine hydrochloride (ESUOM28)

    This evidence summary has been updated and replaced by NICE guideline NG10.

    Withdrawn advice

  10. Chronic pain: oral ketamine (ESUOM27)

    This evidence summary has been updated and replaced by NICE guideline NG193.

    Withdrawn advice

  11. Prostate cancer: triptorelin (Decapeptyl SR) (ESNM30)

    This evidence summary has been updated and replaced by NICE guideline NG131.

    Withdrawn advice

  12. Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Withdrawn advice

  13. Irritable bowel syndrome with constipation in adults: linaclotide (ESNM16)

    This evidence summary has been updated and replaced by NICE guideline CG61.

    Withdrawn advice

  14. Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil (ESNM18)

    This evidence summary has been updated and replaced by NICE guideline CG97.

    Withdrawn advice

  15. Type 1 diabetes: insulin degludec (ESNM24)

    This evidence summary has been updated and replaced by NICE guideline NG17.

    Withdrawn advice